GSK3862995 / GSK - LARVOL DELTA

A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Bronchiectasis • Pulmonary Disease • Respiratory Diseases

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis (clinicaltrials.gov) - P2 | N=400 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P2 trial • Bronchiectasis • Pulmonary Disease • Respiratory Diseases

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis (clinicaltrials.gov) - P2 | N=400 | Not yet recruiting | Sponsor: GlaxoSmithKline

Trial initiation date • Bronchiectasis • Pulmonary Disease • Respiratory Diseases

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis (clinicaltrials.gov) - P2 | N=446 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Bronchiectasis • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Completed | Trial primary completion date: Nov 2025 ➔ Apr 2026

Trial completion • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P1 | N=127 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2027 ➔ Dec 2026 | Trial primary completion date: Mar 2027 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

223977: A study to investigate efficacy, safety, immunogenicity, and pharmacokinetics of GSK3862995B following repeat doses in participants with bronchiectasis aged 18 to 85 years of age inclusive (clinicaltrialsregister.eu) - P1/2 | N=207 | Not yet recruiting | Sponsor: GSK PLC

New P1/2 trial • Bronchiectasis • Pulmonary Disease • Respiratory Diseases

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Jun 2026 ➔ Mar 2027 | Trial primary completion date: Jun 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P1 | N=130 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases